ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

The 41st David A. Karnofsky Memorial Award Lecture: Academic Research Worldwide—Quo Vadis?

(2013) Martine J. Piccart-Gebhart   JOURNAL OF CLINICAL ONCOLOGY

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

Analysis of Fc  Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

(2012) S. A. Hurvitz et al.   CLINICAL CANCER RESEARCH

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Neoadjuvant chemotherapy in breast cancer—insights from the German experience

(2012) Gunter von Minckwitz   Breast Cancer

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

(2011) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy

(2010) Rohit Bhargava et al.   CANCER

Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

(2010) Toru Mukohara   CANCER SCIENCE

p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients

(2010) Maria Stendahl et al.   INTERNATIONAL JOURNAL OF CANCER

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST